Literature DB >> 20544682

Ocular neovascularization following central retinal artery occlusion: prevalence and timing of onset.

Adam K Rudkin1, Andrew W Lee, Celia S Chen.   

Abstract

PURPOSE: Debate exists in the literature on the prevalence and etiology of neovascularization following central retinal artery occlusion (CRAO). The reported prevalence varies from 2.5% to 31.6%. We conducted a retrospective study to determine the prevalence of ocular neovascularization following acute CRAO in our institution.
METHODS: A retrospective audit of consecutive patients with nonarteritic/thromboembolic CRAO presenting between 1997 and 2009 in a single tertiary teaching hospital.
RESULTS: Thirty-three patients were identified as having nonarteritic CRAO, and of this cohort 6 patients (18.2%) developed ocular neovascularization. Neovascular glaucoma was present in 5 cases (15.2%); 2 of these presented through an emergency department with painful eyes, both at 16 weeks post CRAO. The other cases of neovascularization were detected on scheduled follow-ups. Mean time from retinal occlusive event to observed neovascularization was 8.5 weeks (range 2-16 weeks). One case of neovascularization was associated with hemodynamically significant ipsilateral carotid stenosis; no patient had proliferative diabetic retinopathy or other causes of neovascularization.
CONCLUSIONS: The prevalence of neovascularization following acute CRAO in our population was 18.2% at an average of 8.5 weeks post CRAO. There was a temporal relationship between the 2 events and no other causes of neovascularization demonstrable in our cohort of patients. There is no consensus on the follow-up regimen post CRAO to detect ocular neovascularization complications. Our study suggests that neovascularization can occur early and regular follow-up especially in the first 4 months is important post CRAO.

Entities:  

Mesh:

Year:  2010        PMID: 20544682     DOI: 10.1177/112067211002000603

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  16 in total

Review 1.  A review of central retinal artery occlusion: clinical presentation and management.

Authors:  D D Varma; S Cugati; A W Lee; C S Chen
Journal:  Eye (Lond)       Date:  2013-03-08       Impact factor: 3.775

2.  Acute retinal arterial ischemia.

Authors:  Michael Dattilo; Nancy J Newman; Valérie Biousse
Journal:  Ann Eye Sci       Date:  2018-06-06

3.  Reply: 'a review of central retinal artery occlusion: clinical presentation and management'.

Authors:  D Varma; A W Lee; C S Chen
Journal:  Eye (Lond)       Date:  2014-06-06       Impact factor: 3.775

4.  Anti-angiogenic Therapy for Retinal Disease.

Authors:  Yannis M Paulus; Akrit Sodhi
Journal:  Handb Exp Pharmacol       Date:  2017

Review 5.  [Secondary open-angle glaucoma: pseudoexfoliative glaucoma, pigmentary glaucoma and neovascular glaucoma].

Authors:  Roman Greslechner; Horst Helbig; Detlev Spiegel
Journal:  Ophthalmologe       Date:  2022-04-01       Impact factor: 1.059

Review 6.  Neovascular Glaucoma.

Authors:  Shane J Havens; Vikas Gulati
Journal:  Dev Ophthalmol       Date:  2015-10-26

7.  Manifestations of central retinal artery occlusion revealed by fundus fluorescein angiography are associated with the degree of visual loss.

Authors:  Hongxia Gong; Qiuying Song; Lanhui Wang
Journal:  Exp Ther Med       Date:  2016-03-21       Impact factor: 2.447

8.  Ocular neovascularization in eyes with a central retinal artery occlusion or a branch retinal artery occlusion.

Authors:  John O Mason; Shyam A Patel; Richard M Feist; Michael A Albert; Carrie Huisingh; Gerald McGwin; Martin L Thomley
Journal:  Clin Ophthalmol       Date:  2015-06-05

9.  Incidence and Clinical Features of Neovascularization of the Iris following Acute Central Retinal Artery Occlusion.

Authors:  Young Ho Jung; Seong Joon Ahn; Jeong-Ho Hong; Kyu Hyung Park; Moon-Ku Han; Cheolkyu Jung; Se Joon Woo
Journal:  Korean J Ophthalmol       Date:  2016-09-29

10.  Treatment options for central retinal artery occlusion.

Authors:  Sudha Cugati; Daniel D Varma; Celia S Chen; Andrew W Lee
Journal:  Curr Treat Options Neurol       Date:  2013-02       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.